Clinical Trials Logo

Clinical Trial Summary

Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02779257
Study type Interventional
Source University of Maryland, Baltimore
Contact
Status Withdrawn
Phase Phase 4
Start date April 2016
Completion date June 2016

See also
  Status Clinical Trial Phase
Recruiting NCT04614766 - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Phase 1/Phase 2
Completed NCT03220217 - To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Phase 2
Active, not recruiting NCT05050942 - A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET Phase 3
Recruiting NCT03475953 - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06253897 - A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
Recruiting NCT03863106 - The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
Active, not recruiting NCT03972488 - Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Phase 3
Terminated NCT03042780 - FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT03600233 - Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors Phase 2
Completed NCT01423734 - The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases